• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

FDA Approved Nabriva Therapeutics Lefamulin for both Oral and IV Use

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections​.

Nabriva Therapeutics recently published results of the LEAP2 clinical trial investigating XENLETA™ (lefamulin) as an anti-infective agent in community-acquired bacterial pneumonia (CAPB). The Nabriva publication of phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with CABP.

Accelero has been involved in the LEAP2 phase 3 clinical trial for the development and validation of PCR assays detecting several infective pathogens in human sputum specimen.

The results have been published by Alexander E et al in the Journal of the American Medical Association (JAMA), 2019 Sep 27. doi: 10.1001/jama.2019.15468. PubMed ID: 31560372.